Business
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n Patent Issuance Opens Potential to genetically modify cells used to produce ESS Peer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs. original ESS in animals Rare Pediatric Disease Designation and Regenerative Medicine Advanced Therapy designations provide regulatory framework to advance ESS' path to market SAN FRANCISCO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary Cutanogen Corporation was issued United States patent 14/299,480 entitled \"Surgical device for skin therapy or testing\" covering materials and methods for producing Engineered Skin Substitute for the treatment of skin-related conditions and/or testing of potential treatments for skin-related conditions. The patent includes claims relating to the method of manufacturing ESS, methods for adding melanocytes to ESS to improve skin color-matching for patients, and methods for genetically-modifying ESS. The patent extends coverage for ESS through 2022, not including potential patent extensions upon product approval. Once approved, ESS is eligible for 12 years of market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA). \n \"The issuance of this patent in the United States solidifies Cutanogen's leading position in the field of cell therapy for autologous, full-thickness skin products,\" said Gerald Commissiong, CEO of Cutanogen's parent company Amarantus. \"Cutanogen is now refocusing the ESS program towards pediatric severe burns, opening the potential for the company to utilize the Rare Pediatric Disease Designation (RPDD) pathway that has several potential advantages, including a potential Priority Review Voucher. In addition, the 21st Century Cures Act's recently created Regenerative Medicine Advanced Therapy (RMAT) designation provides Cutanogen with additional avenues to accelerate ESS' path to market. Burn physicians worldwide are eager to see ESS come to market to treat the most challenging, life-threatening burn injuries.\" Cutanogen Corporation is currently in the planning phases for the...